

S4 Table. Summary of the pharmacokinetic parameters of OPB-111077 following single and multiple dose administration for the 4-days on/3-days off dosing regimen

Parameter	Dose of OPB-111077		
	300 mg	500 mg	600 mg
Day 1			
No.	4	3	3
C _{max} (ng/mL)	4,230.0±1,640.0	6,130.0±2,290.0	8,450.0±8,210.0
C _{max} /D (ng/mL/mg)	15.4±6.0	13.4±5.0	15.4±14.9
t _{max} (h)	5.0 (3.9-6.0)	4.1 (4.1-6.0)	2.1 (1.0-5.9)
Day 18			
No.	2 ^{a)}	3	5
AUC ₍₀₋₂₄₎ (ng·h/mL)	75,200.0±91,800.0	112,000.0±51,100.0	222,000.0±66,200.0
C _{max} (ng/mL)	4,000.0±7,070.0	7,880.0±2,230.0	15,700.0±4,940.0
t _{max} (hr)	2.0±10.0	2.0 (1.0-6.0)	2.0 (1.0-6.1)
AUC ₍₀₋₂₄₎ /D (ng·hr/mL/mg)	273.0±334.0	245.0±111.0	403.0±120.0
C _{max} /D (ng/mL/mg)	14.5±25.7	17.2±4.9	28.5±9.0
t _{1/2,z} (hr)	12.7±15.1	15.4±2.7	15.5±4.1

Values are presented as mean±standard deviation or median (min-max). C_{max}, maximum observed plasma concentration; C_{max}/D, dose normalized C_{max}; t_{max}, time to maximum observed plasma concentration; AUC₍₀₋₂₄₎, area under the concentration-time from hour 0 to hour 24; AUC₍₀₋₂₄₎/D, dose normalized AUC₍₀₋₂₄₎; T_{1/2,z}, apparent terminal elimination half-life. ^{a)}Arithmetic mean or median not calculated, individual values presented.